This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXMPEB280W7_M.jpg
JPMorgan downgrade the stock to Underweight from Neutral and cut its price target to $5.00 from $10.00, noting it is not surprised by the softer revenue guide given the uncertain macro backdrop and broad-based pullback on marketing budgets, but struggle with the company’s Q1 EBITDA/margin guide despite prior concerns that all revenue was not created equally.
The firm updated its estimates and now forecast Q1/23 revenue of $790 million (down 6% year-over-year) mainly on lower broadcast and digital revenue reflecting lower brand and national advertising.
Meanwhile, Barrington Research downgraded the stock to Market Perform from Outperform.
Shares plunged more than 23% today.
Several analysts, including Roth/MKM, Imperial Capital and CFRA downgraded Ambarella (AMBA) following the company’s announced weak Q1 guidance, despite both Q4 EPS and revenues coming in better than expected.
Roth/MKM downgraded the stock to Neutral from Buy with a price target of $95.00, while CFRA downgraded to Buy from Strong Buy with a price target of $105.00 (from $110.00). Imperial Capital downgraded the company to In-Line from Outperform with a price target of $95.00.
Shares dropped more than 11% today.
JPMorgan downgraded Marqeta Inc. (MQ) to Neutral from Overweight and cut its price target to $6.00 from $9.00.
“While we like the strategic value and long-term operational improvements being put in place at Marqeta, we feel it is time to move to the sideline on the stock given trade-off of lower near-term growth with longer-term certainty due to stepped up renewals including Visa that surprised us to the downside,” the firm said.
Shares plunged more than 22% today following the company’s reported weaker-than-expected guidance, while Q4 results beat estimates.
Wolfe Research downgraded Universal Health Services (UHS) to Peerperform from Outperform.
The company reported its Q4 results, with EPS/revenues coming in better than expected, but annual profit guidance missed the consensus estimates, resulting in a share price drop of more than 8% yesterday.
CFRA downgraded Monster Beverage (MNST) to Hold from Buy and cut its price target to $100.00 from $110.00.
Shares fell more than 2% today after the company’s reported Q4 EPS and revenues missed consensus estimates.
BofA Securities downgraded Woori Financial Group (WF) to Neutral from Buy.
By Davit Kirakosyan
Want this type of news in real-time as it happens? Upgrade to StreetInsider.com Premium Here
